Trials / Completed
CompletedNCT00380653
Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes
A Phase I Pharmacologic Study of Oral Sapacitabine in Patients With Advanced Leukemias or Myelodysplastic Syndromes
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Cyclacel Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this safety/pharmacology study is to determine MTD of sapacitabine when administered in patients with advanced leukemias or myelodysplastic syndromes.
Detailed description
The goal of this study is to find the highest tolerable dose of sapacitabine that can be given to patients with advanced leukemias or myelodysplastic syndromes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | sapacitabine |
Timeline
- Start date
- 2006-01-01
- Primary completion
- 2008-11-01
- Completion
- 2009-06-01
- First posted
- 2006-09-26
- Last updated
- 2021-12-13
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00380653. Inclusion in this directory is not an endorsement.